Myasthenia Gravis Therapeutics – Designation, Collaboration, and Other Developments

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

Get Report Sample at @ http://bit.ly/2DI4cgu

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Pre-Purchase Inquiry at: http://bit.ly/2DVbxN2

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

Myasthenia Gravis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results and Developments

Myasthenia gravis is a neuromuscular disease that leads to varying degrees of skeletal muscle weakness. It is an autoimmune disease resulting from the antibodies blocking or destroying nicotinic acetylcholine receptors at the junction between the nerve and muscle, thus preventing nerve impulses rom triggering muscle contractions. Growth is anticipated in the myasthenia gravis therapeuticspipeline on account of increasing participation of organizations, such as National Organization for Rare Disorder, that support research and development activities in field. The unbearable complications such as difficulty in vision, swallowing, weakness in upper arms and legs and impaired speech are also contributing to the growth of pipeline therapeutics of myasthenia gravis.

Explore Report at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis

In August 2005, Debiopharm S.A. entered into a collaboration with DeveloGen AG for development of PTR-262, a novel peptide drug for the treatment of myasthenia gravis (MG). PTR-262 is derived from the myasthenogenic epitopes of the acetylcholine receptor (AChR) alpha-subunit, which specifically arrests the autoimmune destruction of AChR. Under the terms of the agreement, DeveloGen AG would receive milestone payments and, upon commercialisation of the product, royalties based on revenues of Debiopharm S.A., from worldwide sales. Debiopharm S.A. is an independent company, specialising in oncology, endocrinology and niche products, whereas, DeveloGen AG is a biopharmaceutical company, which mainly focuses on development of novel treatments for metabolic disorders. In March, 2016, Penn centre for innovation had developed therapeutic vaccine for myasthenia gravis. The advantages of vaccine are long lasting benefits, potentially permanent protection, prevention as well as reversal of chronic myasthenia gravis, potent safe and rapid acting.

Request for table of Content at: https://www.psmarketresearch.com/market-analysis/myasthenia-gravis-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of myasthenia gravis therapeutics include UCB Pharma, Ltd. Novartis AG, Grifols Therapeutics Inc., Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, Inc., DeveloGen AG, Debiopharm S.A.